Navigation Links
Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
Date:5/27/2008

pport submitting an NDA for Omigard(TM); our ability to manage licensing opportunities; Cutanea's ability to manage, fund and advance omiganan for dermatological applications into Phase III, the adequacy of Cutanea's Phase II results for regulatory authorities to support advancing to Phase III; our ability to initiate, fund and complete non-clinical studies, clinical studies, manufacturing and all ancillary activities within our expected timelines; and our ability to implement initiatives and operate future expense levels being within our anticipated expectations.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on corporate collaborations; potential delays; uncertainties related to early stage of technology and product development; uncertainties as to the requirement that a drug be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if completed, will not establish the safety or efficacy of our products; uncertainties as to future expense levels and the possibility of unanticipated costs or expenses or cost overruns; the possibility that opportunities will arise that require more cash than presently anticipated and other uncertainties related to predictions of future cash requirements; and other risks and uncertainties which may not be described herein. Certain of these factors and other factors are described in detail in the Company's Annual Information Form and Annual Report on Form 20-F and other filings with the Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission.

Forward-looking statements are based on our current expectations and MIGENIX assumes no obligations to update such information to reflect later events or develo
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 GlassesOff ... image processing functions in the human vision system, announced today ... point guard Chris Paul to develop a ... who want to improve their real-life on-court performance. ... court, whether it is shooting a ball or blocking a ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... customers’ weighing needs and expertly narrows down the product choices to a manageable ... criteria pares down the list to models that fit best with the customer’s ...
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... announced that The Michael J. Fox Foundation for Parkinson,s ... panel of LRRK2 monoclonal antibodies that were developed under ... arrangement the antibodies are being provided at low cost ... LRRK2 therapeutic development efforts. The antibodies will be available ...
... of phase-change materials to readily and swiftly transition between ... source of non-volatile or "flash" memory and data storage. ... been discovered by researchers with the Lawrence Berkeley National ... Berkeley that could be applied to phase change random ...
... Sept. 17 Arizona,s contribution to the accelerated ... help treat suffering patients in the US and ... signing of new deal between Arizona State University ... biopharmaceutical services company which is a leader in ...
Cached Biology Technology:Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation 2Magical BEANs: New nano-sized particles could provide mega-sized data storage 2Magical BEANs: New nano-sized particles could provide mega-sized data storage 3Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement 2
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/10/2015)... 10, 2015 The latest 364 page ... analysis of the global border security market . ... $16.4bn in 2015. Now: Border security is hard ... of the business critical issue you need to know about ... ,s objective analysis of how this will impact your company ...
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... People with intellectual and developmental disabilities living ... to receive routine dental care than those living ... of Dentistry associate professor Catherine Binkley, D.D.S., Ph.D. ... general population to have poor oral hygiene, increased ...
... This release is available in German . Safety ... is how fit the driver is. A research team at the ... Group, managed to develop a sensor system integrated into the steering ... The driver can use his time behind the wheel for a ...
... Nov. 3, 2011 Omnicell, Inc . (NASDAQ: ... and supply management solutions and analytics software for healthcare ... has upgraded its Omnicell supply and medication management ... platform . After nearly a decade as an Omnicell ...
Cached Biology News:UofL researcher to develop oral health plan for those with IDD 2Health check on the road 2Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 2Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 3Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 4
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Profilin-1/2 (FL-140)...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: